Marked reduction of tardive dyskinesia with olanzapine.
Littrell
K H
KH
Johnson
C G
CG
Littrell
S
S
Peabody
C D
CD
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines; D004409:Dyskinesia, Drug-Induced / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D000077152:Olanzapine; D010808:Physical Examination; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine